In some ALK-positive NSCLC patients the development of secondary point mutations in the ALK kinase domain or ALK fusion gene amplification have been shown to be responsible for the acquired resistance to crizotinib [9,12,13]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.